Cogent Biosciences, Inc. (COGT) Operating income 2017–2025
Cogent Biosciences, Inc. (COGT) annual operating income history from SEC filings — each fiscal year as reported.
-$333.4MFY2025 · since FY2017: -$26.2M → -$333.4M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$333.4M | -20.8% |
| FY2024 | -$275.9M | -32.6% |
| FY2023 | -$208.1M | -40.8% |
| FY2022 | -$147.8M | -95.7% |
| FY2021 | -$75.6M | +8.1% |
| FY2020 | -$82.2M | -155.5% |
| FY2019 | -$32.2M | +10.6% |
| FY2018 | -$36.0M | -37.7% |
| FY2017 | -$26.2M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More COGT financial trends
COGT RevenueCOGT Net incomeCOGT Net marginCOGT Gross profitCOGT Gross marginCOGT Operating marginCOGT Operating cash flowCOGT Free cash flowCOGT Capital expendituresCOGT Return on equityCOGT Stock buybacksCOGT Dividends paidCOGT Total assetsCOGT Total liabilitiesCOGT Shareholders’ equityCOGT overview →